Short-course chemotherapy for extrapulmonary tuberculosis. Nine years' experience

Area of Science:

• Infectious Diseases
• Pharmacology
• Public Health

Background:

• Short-course chemotherapy is established for pulmonary tuberculosis but not extrapulmonary TB.
• Extrapulmonary tuberculosis requires effective, manageable treatment regimens.

Purpose of the Study:

• To evaluate the efficacy and safety of a 9-month short-course chemotherapy regimen for extrapulmonary tuberculosis.
• To assess patient acceptance and feasibility of self-administered, twice-weekly drug administration.

Main Methods:

• A 9-year retrospective study of 350 patients with extrapulmonary tuberculosis treated with a 9-month regimen of isoniazid and rifampin.
• Therapy was largely self-administered, with direct supervision in less than 2% of cases.
• Surgical intervention (drainage and debridement) was utilized for bone lesions.

Main Results:

• The 9-month short-course chemotherapy regimen achieved a 95% success rate in treating extrapulmonary tuberculosis.
• This success rate is comparable to conventional 18-24 month therapies.
• Early surgical intervention in bone lesions significantly enhanced healing.
• The regimen demonstrated excellent patient acceptance, short duration, and modest toxicity.

Conclusions:

• A 9-month short-course chemotherapy regimen of isoniazid and rifampin is effective for extrapulmonary tuberculosis.
• The twice-weekly, largely self-administered regimen is cost-effective, well-tolerated, and feasible for public health nursing supervision.
• This approach offers a viable alternative to prolonged conventional treatments for extrapulmonary TB.